BR9908132A - Composição farmacêutica lìquida para administração oral - Google Patents

Composição farmacêutica lìquida para administração oral

Info

Publication number
BR9908132A
BR9908132A BR9908132-6A BR9908132A BR9908132A BR 9908132 A BR9908132 A BR 9908132A BR 9908132 A BR9908132 A BR 9908132A BR 9908132 A BR9908132 A BR 9908132A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
oral administration
agents
benzoxazinone
Prior art date
Application number
BR9908132-6A
Other languages
English (en)
Other versions
BRPI9908132B8 (pt
BRPI9908132B1 (pt
Inventor
Surendra M Bahal
Michael B Maurin
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of BR9908132A publication Critical patent/BR9908132A/pt
Publication of BRPI9908132B1 publication Critical patent/BRPI9908132B1/pt
Publication of BRPI9908132B8 publication Critical patent/BRPI9908132B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<B>"COMPOSIçãO FARMACêUTICA LìQUIDA PARA ADMINISTRAçãO ORAL"<D> A presente invenção trata de uma composição farmacêutica líquida oral palatável de compostos de benzoxazinona utilizáveis como inibidores da transcriptase reversa de HIV, a qual compreende o ingrediente ativo de benzoxazinona em um veículo líquido que compreende triglicerídios de ácidos graxos de cadeias médias. Outros agentes de formulação, tais como agentes adoçantes, agentes de suspensão de lecitina, etc., podem ser opcionalmente adicionados.
BRPI9908132A 1998-02-17 1999-02-17 composição farmacêutica líquida para administração oral BRPI9908132B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7488198P 1998-02-17 1998-02-17
PCT/US1999/003318 WO1999040921A2 (en) 1998-02-17 1999-02-17 Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors

Publications (3)

Publication Number Publication Date
BR9908132A true BR9908132A (pt) 2000-12-05
BRPI9908132B1 BRPI9908132B1 (pt) 2015-07-14
BRPI9908132B8 BRPI9908132B8 (pt) 2016-11-16

Family

ID=22122226

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI9908132A BRPI9908132B8 (pt) 1998-02-17 1999-02-17 composição farmacêutica líquida para administração oral
BRPI9908132A BRPI9908132C1 (pt) 1998-02-17 1999-02-17 composição farmacêutica líquida para administração oral

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI9908132A BRPI9908132C1 (pt) 1998-02-17 1999-02-17 composição farmacêutica líquida para administração oral

Country Status (19)

Country Link
US (1) US6235733B1 (pt)
EP (1) EP1054674B1 (pt)
JP (1) JP2002502878A (pt)
CN (1) CN1170541C (pt)
AR (1) AR018092A1 (pt)
AT (1) ATE345802T1 (pt)
AU (1) AU745008C (pt)
BR (2) BRPI9908132B8 (pt)
CA (1) CA2319609C (pt)
DE (1) DE69934097T2 (pt)
ES (1) ES2277429T3 (pt)
HK (1) HK1030749A1 (pt)
HR (1) HRP990049A2 (pt)
IL (1) IL137763A0 (pt)
MY (1) MY139034A (pt)
NZ (1) NZ506579A (pt)
TW (1) TW528596B (pt)
WO (1) WO1999040921A2 (pt)
ZA (1) ZA99981B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018071547A1 (en) * 2016-10-11 2018-04-19 Aucta Pharmaceuticals Powder for oral suspension containing lamotrigine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0484281B2 (en) * 1990-11-02 2000-11-22 Novartis AG Cyclosporins
US5494936A (en) * 1992-04-27 1996-02-27 Vyrex Corporation Delivery formulation for probucol
US5663169A (en) 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
WO1995020389A1 (en) 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
JP2000509392A (ja) 1996-05-02 2000-07-25 メルク エンド カンパニー インコーポレーテッド Ａｉｄｓの治療に有効なｈｉｖプロテアーゼ阻害剤
ATE248826T1 (de) * 1996-10-02 2003-09-15 Bristol Myers Squibb Pharma Co 4,4-disubstituierte 1,4-dihydro-2h-3,1-benzoxazin-2-one die anwendbar sind als hiv- reverstranskriptase-inhibitoren, zwischenprodukte und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
TW528596B (en) 2003-04-21
CN1291098A (zh) 2001-04-11
HK1030749A1 (en) 2001-05-18
EP1054674B1 (en) 2006-11-22
DE69934097D1 (de) 2007-01-04
US6235733B1 (en) 2001-05-22
NZ506579A (en) 2002-11-26
AU2682799A (en) 1999-08-30
AU745008C (en) 2003-03-27
AR018092A1 (es) 2001-10-31
CA2319609A1 (en) 1999-08-19
AU745008B2 (en) 2002-03-07
BRPI9908132C1 (pt) 2021-05-25
EP1054674A2 (en) 2000-11-29
WO1999040921A2 (en) 1999-08-19
CA2319609C (en) 2007-09-18
BRPI9908132B8 (pt) 2016-11-16
DE69934097T2 (de) 2007-06-28
MY139034A (en) 2009-08-28
IL137763A0 (en) 2001-10-31
WO1999040921A3 (en) 1999-11-04
JP2002502878A (ja) 2002-01-29
ZA99981B (en) 2000-08-08
CN1170541C (zh) 2004-10-13
ATE345802T1 (de) 2006-12-15
HRP990049A2 (en) 1999-12-31
BRPI9908132B1 (pt) 2015-07-14
ES2277429T3 (es) 2007-07-01

Similar Documents

Publication Publication Date Title
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
CA2207835A1 (fr) Nouveaux derives du 3-(piperid-4-yl) 1,2-benzisoxazole et du 3-(piperazin-4-yl) 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
HRP20010615B1 (en) Pharmaceutical compositions containing proton pump inhibitors
AR025959A1 (es) DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
AR007827A1 (es) 3-ureido-piridofuranos y -piridotiofenos, procedimiento para su preparacion, composicion que los comprende y uso de dichos compuestos para lapreparacion de medicamentos.
BR9907647A (pt) Composições contendo composto orgânicos
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
IT1288290B1 (it) Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
BRPI0513673A (pt) método para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, veìculo utilizado na administração enteral de compostos biologicamente ativos, composição farmacêutica e uso de uma quantidade eficaz de um ou mais derivados de fosfato
BR0014818A (pt) Imidazo-3-il-aminas bicìclicas procedimento de preparação e medicamentos que contém como substância ativa pelo menos uma imidazo-3-il-amina bicìclica
CO5280050A1 (es) Desnaturalizantes para las sales aminas simpaticomimeticas
BR0111126A (pt) Derivados de aminoácidos cìclicos úteis como agentes farmacêuticos
TR200003108T2 (tr) İlaç kompozisyonları
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
ES2151698T3 (es) Nuevos derivados de 6-hidroxi y 6-oxo-androstan activos sobre el sistema cardiovascular y composiciones farmaceuticas que los contienen.
ATE440838T1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
AR045912A1 (es) Composiciones farmaceuticas que contienen derivados de azetidina
BR9908132A (pt) Composição farmacêutica lìquida para administração oral
PA8496701A1 (es) Polimorfos de un diclorhidrato cristalino de azobiciclo [2.2.2] oct- 3 - ilamina y sus composiciones farmaceuticas
ATE236885T1 (de) Hydrazono-benzazulen-derivate, pharmazeutische zusammensetzungen und zwischenprodukte
PA8444901A1 (es) Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios
DE69809435D1 (de) Inhibitor- und konservierungsmittelzusammensetzung

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO ESTABELECIDO PELOS ARTIGOS 8O E 13 DA LPI (LEI 9729/96)

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/07/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI NO 2323 DE 14/07/2015, QUANTO AO ENDERECO DO TITULAR.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/02/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 17/02/2019